AREV Life Sciences Global (AREV Life Sciences Global) 3-Year EBITDA Growth Rate : 49.50% (As of Sep. 2023)

View and export this data going back to 2019. Start your Free Trial

What is AREV Life Sciences Global 3-Year EBITDA Growth Rate?

AREV Life Sciences Global's EBITDA per Share for the three months ended in Sep. 2023 was $0.00.

During the past 3 years, the average EBITDA Per Share Growth Rate was 49.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 52.10% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 48.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of AREV Life Sciences Global was 77.00% per year. The lowest was -49.50% per year. And the median was 44.10% per year.

Competitive Comparison of AREV Life Sciences Global's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, AREV Life Sciences Global's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AREV Life Sciences Global's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AREV Life Sciences Global's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where AREV Life Sciences Global's 3-Year EBITDA Growth Rate falls into.

AREV Life Sciences Global 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

AREV Life Sciences Global (OTCPK:AREVF) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

AREV Life Sciences Global 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of AREV Life Sciences Global's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

AREV Life Sciences Global (AREV Life Sciences Global) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AREV Life Sciences Global Corp (OTCPK:AREVF) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

91 Golden Drive, Unit 18, Coquitlam, BC, CAN, V3K 6R2

Website

https://www.arevlifesciences.com

AREV Life Sciences Global Corp is a fully integrated, early stage life science discovery enterprise dedicated to delivering solutions to public healthcare metrics through innovations and successful collaborations in the life science industry. The Company's focuses on dedication to generate revenue by way of novel therapeutic approaches to human nutrition and malnutrition, pandemic diseases, and neglected chronic co-morbidities.

AREV Life Sciences Global (AREV Life Sciences Global) Headlines

From GuruFocus

Kevin Phelps, CPA Appointed Chief Operating Officer of Arev Life Sciences Global Corporation & Warrant Offering

By GuruFocusNews GuruFocusNews • 04-21-2022

AREV Life Sciences Global Corporation announces engagement of TransBIOTech to facilitate preclinical therapeutic pipeline development

By GuruFocusNews GuruFocusNews • 04-21-2022

AREV Life Sciences Advances Developments, New Appointments and Relationships

By GuruFocusNews GuruFocusNews • 02-17-2022

AREV Life Sciences Completes Lab and Fungi Fruiting Room Build

By GuruFocusNews GuruFocusNews • 02-23-2022